Suppr超能文献

年龄较大对软组织肉瘤放疗相关结局有影响。

Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.

作者信息

Yuen Noah K, Li Chin-Shang, Monjazeb Arta M, Borys Dariusz, Bold Richard J, Canter Robert J

机构信息

Division of Surgical Oncology, Department of Surgery, UC Davis School of Medicine, Sacramento, California.

Division of Biostatistics, Department of Public Health Sciences, UC Davis, Sacramento, California.

出版信息

J Surg Res. 2015 Dec;199(2):494-504. doi: 10.1016/j.jss.2015.06.020. Epub 2015 Jun 16.

Abstract

BACKGROUND

Radiation therapy (RT) is a standard component in the multimodality management of localized soft tissue sarcoma (STS). Increasing studies are focusing on biological modifiers that may influence the host's response to RT, including immunologic mechanisms known to change with the aging process. We hypothesized that the effects of RT would be influenced by age, contributing to differences in treatment outcome.

METHODS

Using Surveillance, Epidemiology, and End Results (1990-2011), we identified 30,898 adult patients (>18 y) with nonmetastatic STS undergoing initial surgery. We compared patient demographics, tumor characteristics, and treatments by age. Multivariable analyses were used to analyze overall survival (OS) and disease-specific survival (DSS). Hazard ratios (HRs) were calculated based on multivariable Cox proportional hazards models.

RESULTS

Mean age at diagnosis was 56.6 ± 16.8 y, and 33.6% of patients were ≥65 y. Of the total, 52.1% of patients were male and 67% were white; 59.9% of patients underwent surgery alone, 33.3% received adjuvant RT, and 6.8% neoadjuvant RT. On multivariable analysis, age, sex, year of diagnosis, histology, grade, size, marital status, and RT predicted OS, whereas age, year of diagnosis, ethnicity, histology, site, grade, RT, size, and marital status predicted DSS. In all patients, RT was associated with improved OS and DSS compared to surgery alone (median OS 136 ± 13 mo with RT versus 118 ± 9 mo without RT and 5-y OS 63.2 ± 1.4% with RT versus 60.5 ± 1.2% without, P < 0.01). Patients ≥65 y derived greater improvements in OS and DSS compared with patients <65 y. These benefits were most notable after neoadjuvant RT with patients ≥65 y having significantly better OS (HR = 0.63; 95% confidence interval = 0.53-0.75), whereas patients <65 y did not (HR = 0.96; 95% confidence interval = 0.83-1.10). In addition, interaction testing demonstrated a significant modifier effect between RT and age (P < 0.05).

CONCLUSIONS

RT is associated with improved survival in patients with STS undergoing surgical treatment, but improvements in oncologic outcome with RT were greatest among older patients. Further studies into the mechanism of these age-related effects are needed.

摘要

背景

放射治疗(RT)是局限性软组织肉瘤(STS)多模式治疗的标准组成部分。越来越多的研究聚焦于可能影响宿主对RT反应的生物调节剂,包括已知随衰老过程而变化的免疫机制。我们假设RT的效果会受年龄影响,从而导致治疗结果的差异。

方法

利用监测、流行病学和最终结果(1990 - 2011年),我们确定了30898例接受初次手术的非转移性STS成年患者(>18岁)。我们按年龄比较了患者的人口统计学特征、肿瘤特征和治疗情况。多变量分析用于分析总生存期(OS)和疾病特异性生存期(DSS)。基于多变量Cox比例风险模型计算风险比(HRs)。

结果

诊断时的平均年龄为56.6±16.8岁,33.6%的患者年龄≥65岁。总体而言,52.1%的患者为男性,67%为白人;59.9%的患者仅接受手术,33.3%接受辅助RT,6.8%接受新辅助RT。多变量分析显示,年龄、性别、诊断年份、组织学类型、分级、大小、婚姻状况和RT可预测OS,而年龄、诊断年份、种族、组织学类型、部位、分级、RT、大小和婚姻状况可预测DSS。在所有患者中,与单纯手术相比,RT与OS和DSS的改善相关(接受RT的患者中位OS为136±13个月,未接受RT的为118±9个月;5年OS率接受RT的为63.2±1.4%,未接受的为60.5±1.2%,P<0.01)。与<65岁的患者相比,≥65岁的患者在OS和DSS方面有更大改善。这些益处在新辅助RT后最为显著,≥65岁的患者OS明显更好(HR = 0.63;95%置信区间 = 0.53 - 0.75),而<65岁的患者则不然(HR = 0.96;95%置信区间 = 0.83 - 1.10)。此外,交互作用检验显示RT和年龄之间存在显著的调节效应(P<0.05)。

结论

RT与接受手术治疗的STS患者生存率的提高相关,但RT在肿瘤学结局方面的改善在老年患者中最为显著。需要进一步研究这些与年龄相关效应的机制。

相似文献

1
Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.
J Surg Res. 2015 Dec;199(2):494-504. doi: 10.1016/j.jss.2015.06.020. Epub 2015 Jun 16.
5
7
Predicting survival for well-differentiated liposarcoma: the importance of tumor location.
J Surg Res. 2012 Jun 1;175(1):12-7. doi: 10.1016/j.jss.2011.07.024. Epub 2011 Aug 10.
9
The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population.
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):894-902. doi: 10.1016/j.ijrobp.2014.07.046. Epub 2014 Oct 18.

本文引用的文献

1
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Cell Immunol. 2015 Mar;294(1):54-9. doi: 10.1016/j.cellimm.2015.02.003. Epub 2015 Feb 10.
3
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
4
6
Assessment of multimodality therapy use for extremity sarcoma in the United States.
J Surg Oncol. 2014 Apr;109(5):395-404. doi: 10.1002/jso.23520. Epub 2013 Dec 20.
7
Regulatory T cells and the immune aging process: a mini-review.
Gerontology. 2014;60(2):130-7. doi: 10.1159/000355303. Epub 2013 Nov 28.
8
Natural and induced T regulatory cells in cancer.
Front Immunol. 2013 Jul 11;4:190. doi: 10.3389/fimmu.2013.00190. eCollection 2013.
9
Radiotherapy of human sarcoma promotes an intratumoral immune effector signature.
Clin Cancer Res. 2013 Sep 1;19(17):4843-53. doi: 10.1158/1078-0432.CCR-13-0352. Epub 2013 Jul 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验